

- and a method of producing the polypeptide, classified in class 435, subclass 69.1.
- II. Claims 1-2, 4-7, drawn to a polynucleotide of SEQ ID NO:6, an expression vector, a host cell, and a method of producing the polypeptide, classified in class 435, subclass 69.1.
- III. Claims 8-13, drawn to an isolated polypeptide of SEQ ID NO: 2, classified in class 530, subclass 350.
- IV. Claims 14-15, drawn to antibodies that bind SEQ ID NO: 2, classified in class 530, subclass 387.1.
- V. Claims 16-19, drawn to a method of administration of a polypeptide of SEQ ID NO:2, classified in class 514, subclass 2.
- VI. Claim 20, drawn to a method of delivering a drug to heart tissue wherein the drug is fused to an FGF homologue polypeptide, classified in class 424, subclass 192.1.

In response to the Requirement for Restriction Election, Applicant elects without traverse Group III, Claims 8-13. Claims 1-7, 14-20 are withdrawn (and cancelled, see enclosed Preliminary Amendment) from the case; however, Applicant reserves the right to pursue and prosecute these claims in continuation and divisional applications.

Early action upon and allowance of this application are requested. If for any reason the Examiner feels that a telephone conference would expedite prosecution of the application, the Examiner is invited to telephone the undersigned at (206) 442-6627.

Respectfully Submitted,



Michelle L. Johnson
Registration No. 36,352

Enclosures: Request for Extension of Time (in duplicate)
Preliminary Amendment
Authorization to Act in a Representative Capacity
Postcard